Loading...
In the debate over the high costs of new interferon-free and ribavirin-free regimens for hepatitis C virus (HCV) infection, the real cost of previous-generation, protease inhibitor– and interferon-based regimens in clinical practice should be taken into account.
In a single-center study, investigators identified patients who had undergone telaprevir-based therapy for genotype 1 HCV infection and calculated their use of resources and costs, including pretreatment costs (lab and imaging tests, office visits), on-treatment costs (labs, office visits, cost of therapy, adverse-effect management), and posttreatment costs (labs, office visits, adverse-effect management). Direct costs were calculated using RED BOOK, the Healthcare Cost and Utilizati…